Quick answer
The process by which food leaves the stomach into the small intestine. GLP-1 medications slow gastric emptying, which prolongs fullness and contributes to many of the common GI side effects.
Full definition
Gastric emptying is the gradual passage of partially digested food (chyme) from the stomach into the duodenum. Normal half-emptying time is roughly 30-90 minutes depending on meal composition. GLP-1 RAs significantly slow gastric emptying, an effect strongest at initiation and partially attenuated with chronic dosing. Slowed emptying contributes to satiety and post-meal glucose smoothing but also drives nausea, bloating, early satiety, and in rare cases gastroparesis. The American Society of Anesthesiologists issued guidance (2023) on holding GLP-1s before elective procedures due to aspiration risk.
Deep dive
Gastric Emptying: complete reference
Gastric emptying is the rate at which food and liquid leave the stomach and enter the small intestine — a key determinant of post-meal blood glucose rise, satiety duration, and digestive comfort. Normal gastric emptying half-time is 90-120 minutes for solids. GLP-1 receptor agonists slow gastric emptying by 30-70% depending on dose and individual response, creating multiple downstream effects: prolonged stomach fullness (enhances satiety), blunted post-meal glucose spikes (improves glycemic control), and reduced caloric absorption rate (contributes to weight loss). The slowed emptying is also responsible for most GI side effects (nausea, reflux, vomiting risk) — especially during titration weeks when delivery rates change. Patients with pre-existing gastroparesis are typically contraindicated for GLP-1 therapy because the additive delay can cause severe symptoms. Imaging studies (gastric emptying scintigraphy) confirm the effect; clinically, patients report "feeling food stay in stomach" especially with high-fat or high-fiber meals.
- In practice
- On Ozempic, your post-meal sense of fullness may last 3-4 hours longer than before — food literally stays in your stomach longer, slowing how quickly carbs become blood sugar.
- Clinical context
- Delayed gastric emptying is both therapeutic benefit and source of GI side effects. Patients with gastroparesis are usually excluded.
Medications
Gastric Emptying is most directly relevant to the following GLP-1 medications:
Related terms
- Gastroparesis — A condition of delayed stomach emptying without mechanical obstruction. GLP-1 medications can cause …
- Satiety — The physiological feeling of fullness that ends eating and suppresses further intake between meals. …
- GLP-1 (Glucagon-Like Peptide-1) — GLP-1 is a natural gut hormone (incretin) released after eating that triggers insulin release, slows…
Continue learning
GLP1Zoom glossary is educational reference. Definitions are summary interpretations of clinical sources and not a substitute for prescribing-information detail. Full disclaimer.
References
Glucagon-Like Peptide-1 Receptor Agonists: Mechanisms и Clinical Use (Drucker, Cell Metabolism)(2018)
Tirzepatide GIP/GLP-1 Dual Agonism: Mechanism Review (Lancet Diabetes & Endocrinology)(2021)
GLP-1 Effects on Gastric Emptying: Pharmacology Review (American J Physiology)(2020)
Endocrine Society Clinical Practice Guideline: Pharmacological Management of Obesity(2015)
STEP-1 trial: Once-Weekly Semaglutide in Adults with Overweight or Obesity (Wilding et al., NEJM)(2021)
SURMOUNT-1 trial: Tirzepatide Once Weekly для Treatment of Obesity (Jastreboff et al., NEJM)(2022)
SUSTAIN-6 trial: Semaglutide and Cardiovascular Outcomes (Marso et al., NEJM)(2016)
SURPASS-2 trial: Tirzepatide vs Semaglutide в Type 2 Diabetes (Frias et al., NEJM)(2021)
LEADER trial: Liraglutide and Cardiovascular Outcomes в T2D (Marso et al., NEJM)(2016)